scholarly journals Pilot Clinical Trial of Time-Restricted Eating in Patients with Metabolic Syndrome

Nutrients ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 346
Author(s):  
Iwona Świątkiewicz ◽  
Celestyna Mila-Kierzenkowska ◽  
Alina Woźniak ◽  
Karolina Szewczyk-Golec ◽  
Jarosław Nuszkiewicz ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Dietary Intake ◽  
Large Scale ◽  
Controlled Trial ◽  
European Population ◽  
Cardiac Biomarkers ◽  
Cardiometabolic Health ◽  
And Behavior

Metabolic syndrome (MetS) and erratic eating patterns are associated with circadian rhythm disruption which contributes to an increased cardiometabolic risks. Restricting eating period (time-restricted eating, TRE) can restore robust circadian rhythms and improve cardiometabolic health. We describe a protocol of the Time-Restricted Eating on Metabolic and Neuroendocrine homeostasis, Inflammation, and Oxidative Stress (TREMNIOS) pilot clinical trial in Polish adult patients with MetS and eating period of ≥14 h/day. The study aims to test the feasibility of TRE intervention and methodology for evaluating its efficacy for improving metabolic, neuroendocrine, inflammatory, oxidative stress and cardiac biomarkers, and daily rhythms of behavior for such population. Participants will apply 10-h TRE over a 12-week monitored intervention followed by a 12-week self-directed intervention. Changes in eating window, body weight and composition, biomarkers, and rhythms of behavior will be evaluated. Dietary intake, sleep, activity and wellbeing will be monitored with the myCircadianClock application and questionnaires. Adherence to TRE defined as the proportion of days recorded with app during the monitored intervention in which participants satisfied 10-h TRE is the primary outcome. TREMNIOS will also provide an exploratory framework to depict post-TRE changes in cardiometabolic outcomes and behavior rhythms. This protocol extends previous TRE-related protocols by targeting European population with diagnosed MetS and including long-term intervention, validated tools for monitoring dietary intake and adherence, and comprehensive range of biomarkers. TREMNIOS trial will lay the groundwork for a large-scale randomized controlled trial to determine TRE efficacy for improving cardiometabolic health in MetS population.

Changing the Obesogenic Environment to Improve Cardiometabolic Health in Residential Patients with a Severe Mental Illness: ELIPS, a Randomized Controlled Trial

2017 ◽  
Vol 41 (S1) ◽  
pp. S267-S268 ◽  
Author(s):  
F. Jörg ◽  
A. Looijmans ◽  
A. Stiekema ◽  
L. Van der Meer ◽  
R. Schoevers ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Controlled Trial ◽  
Clinical Care ◽  
Pragmatic Trial ◽  
Intervention Group ◽  
Cardiometabolic Health ◽  
Control Group ◽  
Obesogenic Environment ◽  
Randomized Controlled ◽  
Small Change

IntroductionThe life expectancy of severe mentally ill (SMI) patients is shortened up to 30 years, due to cardiometabolic diseases, partly caused by unhealthy lifestyles behaviors. In residential facilities, adopting a healthy lifestyle is hampered by the obesogenic environment; an obesity promoting environment.ObjectiveTo determine, the effectiveness of a 12 month lifestyle intervention addressing the obesogenic environment to improve cardiometabolic health of SMI residential patients.MethodsThe effectiveness of lifestyle interventions in psychiatry (ELIPS) trial is a multi-site, cluster randomized controlled pragmatic trial. Twenty-nine sheltered and long-term clinical care teams serving SMI patients in the Netherlands were randomized into intervention (n = 15) or control (n = 14) arm, including 736 patients (73% psychotic disorder, 63% male, 48 ± 13 years). The intervention aimed to improve the obesogenic environment using a small change approach with a focus on nutrition and physical activity. Primary outcome was waist circumference (WC) after three and twelve month's intervention. Secondary outcomes were BMI and metabolic syndrome.ResultsGeneral linear mixed models adjusted for age, gender, housing facility and antipsychotic medication showed that WC significantly decreased with 1.51 cm (95%CI = −2.99;−0.04, Cohen's d = 0.07) in the intervention group compared to control group after three months and tended to remain lower with 1.28 cm (95%CI = −2.79; 0.23, Cohen's d = 0.06) after twelve months. Metabolic syndrome Z-score decreased after three months with 0.225 SD (95% CI = −0.4038;−0.096, Cohen's d = 0.20), mainly due to lower fasting glucose and WC. No significant effects were found on BMI.ConclusionA small change approach targeting the obesogenic environment of SMI residential patients reduces cardiometabolic risk.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Influence of daily fresh pear consumption on biomarkers of cardiometabolic health in middle-aged/older adults with metabolic syndrome: a randomized controlled trial

2019 ◽  
Vol 10 (2) ◽  
pp. 1062-1072
Author(s):  
Negin Navaei ◽  
Shirin Pourafshar ◽  
Neda S. Akhavan ◽  
Nicole S. Litwin ◽  
Elizabeth M. Foley ◽  
...  
Keyword(s):  
Older Adults ◽  
Metabolic Syndrome ◽  
Randomized Controlled Trial ◽  
Functional Food ◽  
Controlled Trial ◽  
Cardiometabolic Health ◽  
Middle Aged ◽  
Randomized Controlled

Previous research suggests potential for fresh pears as a functional food for promoting cardiometabolic health.

scholarly journals Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: A randomized controlled trial

2020 ◽  
Author(s):  
Yan Gong ◽  
Kun Zhang ◽  
Dongsheng Xiong ◽  
Jiajing Wei ◽  
Hao Tan ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Clinical Trial ◽  
Growth Hormone ◽  
Endometrial Thickness ◽  
Controlled Trial ◽  
Stress Index ◽  
Ivf Outcomes ◽  
Embryo Formation ◽  
Poor Ovarian Responders ◽  
Ivf Et

Abstract Background: Oxidative stress (OS), defined as an imbalance between excessive reactive oxygen species (ROS) and/or reactive nitrogen species (RNS) production and antioxidant insufficiency, has been suggested to be involved in the pathogenesis of poor ovarian response (POR). Growth hormone (GH) can reduce OS in some cell types. This study investigated whether GH can improve OS and the in vitro fertilization and embryo transfer (IVF-ET) outcomes of poor ovarian responders.Methods: This study enrolled 105 patients with POR and 58 patients without POR (controls) who were diagnosed according to the Bologna criteria and underwent conventional IVF-ET. Poor ovarian responders were randomly assigned to two groups: the POR-GH group, which received pretreatment with GH 4 IU/d on day 2 of the previous menstrual cycle before IVF until the trigger day, and the POR-C group, which received no pretreatment. OS markers in follicular fluid (FF), ROS levels in granulosa cells (GCs), and the IVF outcomes of the groups were compared.Result(s): Endometrial thickness on trigger day, the number of cleaved embryos, the number of higher-quality embryos, and the rates of embryo formation, higher-quality embryo formation, implantation and clinical pregnancy were significantly increased in the POR-GH group compared with the POR-C group (P < 0.05). Moreover, compared to those in the non-POR group, FF malondialdehyde (MDA), total oxidant status (TOS), oxidative stress index (OSI) and ROS levels in GCs were significantly higher, whereas superoxide dismutase (SOD) and the total antioxidant capacity (TAC) were significantly lower in the POR-C group (P < 0.05). Furthermore, compared with those in the POR-C group, the FF TAC was significantly increased in the POR-GH group, and TOS, OSI and intracellular ROS levels were significantly reduced (P < 0.05).Conclusion(s): Pretreatment with GH alleviates OS and improves oocyte quality and IVF outcomes of poor ovarian responders.Clinical Trial Registration: Chinese Clinical Trial Registry. ChiCTR1900021269. Registered 8 February 2019, http://www.chictr.org.cn/edit.aspx?pid=35837&htm=4.

Oxidative Stress Markers Diagnostic Value in Metabolic Syndrome Dermal Manifestations: a Prospective Clinical Trial

2018 ◽  
Author(s):  
Julija Voicehovska ◽  
Mila Vlaskovska ◽  
Jana Janovska ◽  
Sergejs Babikovs ◽  
Vladimirs Voicehovskis ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Diagnostic Value ◽  
Prospective Clinical Trial ◽  
Oxidative Stress Markers ◽  
Stress Markers

Blueberry supplementation attenuates oxidative stress within monocytes and modulates immune cell levels in adults with metabolic syndrome: a randomized, double-blind, placebo-controlled trial

2017 ◽  
Vol 8 (11) ◽  
pp. 4118-4128 ◽  
Author(s):  
Anand R. Nair ◽  
Nithya Mariappan ◽  
April J. Stull ◽  
Joseph Francis
Keyword(s):  
Oxidative Stress ◽  
Metabolic Syndrome ◽  
Immune Cell ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Blueberry Supplementation

Blueberry supplementation for six weeks significantly attenuated oxidative stress in the monocytes in patients with MetS.

Galantamine in the Treatment of Vascular Dementia

2003 ◽  
Vol 15 (S1) ◽  
pp. 187-193 ◽  
Author(s):  
H. Robert Brashear
Keyword(s):  
Vascular Dementia ◽  
Large Scale ◽  
Controlled Trial ◽  
Treatment Options ◽  
Treatment Strategies ◽  
Acetylcholinesterase Inhibitors ◽  
Symptomatic Therapy ◽  
Cognitive Benefits ◽  
And Behavior

Vascular dementia (VaD) is a disorder with no cure and limited treatment options. Similarities between VaD and Alzheimer's disease (AD) arise on a number of levels. Both involve progressive decline in cognition, functional ability, and behavior, and there is evidence for a central role of reduced cholinergic neurotransmission in the two illnesses. Treatment strategies in VaD have historically focused on prevention, although evidence of cognitive benefits with preventative treatment is scarce. Acetylcholinesterase inhibitors represent a rational treatment possibility for symptomatic therapy of patients with VaD. A recent large-scale trial of galantamine in patients with VaD or AD with cerebrovascular disease (AD + CVD) represents the first placebo-controlled trial showing clinically relevant benefits in these important patient populations.

Açaí (Euterpe oleracea Mart.) beverage consumption improves biomarkers for inflammation but not glucose- or lipid-metabolism in individuals with metabolic syndrome in a randomized, double-blinded, placebo-controlled clinical trial

2018 ◽  
Vol 9 (6) ◽  
pp. 3097-3103 ◽  
Author(s):  
Hyemee Kim ◽  
Sunday Y. Simbo ◽  
Chuo Fang ◽  
Lilly McAlister ◽  
Andrea Roque ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Lipid Metabolism ◽  
Controlled Clinical Trial ◽  
Euterpe Oleracea ◽  
Beverage Consumption ◽  
Double Blinded ◽  
And Oxidative Stress ◽  
Euterpe Oleracea Mart

Açaí beverage consumption may reduce biomarkers for inflammation and oxidative stress in metabolic syndrome.

Oxidative Stress Markers Diagnostic Value in Metabolic Syndrome Dermal Manifestations: a Prospective Clinical Trial

2018 ◽  
Author(s):  
Julija Voicehovska ◽  
Mila Vlaskovska ◽  
Jana Janovska ◽  
Sergejs Babikovs ◽  
Vladimirs Voicehovskis ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Diagnostic Value ◽  
Prospective Clinical Trial ◽  
Oxidative Stress Markers ◽  
Stress Markers
Sign in / Sign up

Export Citation Format

Share Document